Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany?
Objectives: Our study explores whether, and how, different methodological choices are associated with different health technology assessment (HTA) outcomes. We focus on the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) in Germany and the National Institute for Health and Care Excellenc...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 Dec 2018
|
| In: |
Expert review of pharmacoeconomics and outcomes research
Year: 2019, Jahrgang: 19, Heft: 4, Pages: 453-462 |
| ISSN: | 1744-8379 |
| DOI: | 10.1080/14737167.2019.1559732 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1080/14737167.2019.1559732 Verlag: https://doi.org/10.1080/14737167.2019.1559732 
|
| Verfasserangaben: | Ramon Schaefer & Michael Schlander |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1683541901 | ||
| 003 | DE-627 | ||
| 005 | 20220817164511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191126s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737167.2019.1559732 |2 doi | |
| 035 | |a (DE-627)1683541901 | ||
| 035 | |a (DE-599)KXP1683541901 | ||
| 035 | |a (OCoLC)1341278752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schäfer, Ramon |d 1988- |e VerfasserIn |0 (DE-588)1200443306 |0 (DE-627)168354532X |4 aut | |
| 245 | 1 | 0 | |a Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany? |c Ramon Schaefer & Michael Schlander |
| 264 | 1 | |c 30 Dec 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.11.2019 | ||
| 520 | |a Objectives: Our study explores whether, and how, different methodological choices are associated with different health technology assessment (HTA) outcomes. We focus on the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) in Germany and the National Institute for Health and Care Excellence (NICE) in England. Both agencies may be considered as exemplars for the application of the principles of evidence-based medicine and the logic of cost-effectiveness, respectively.Methods: We extracted data from all publically available G-BA appraisals until April 2015, as well as all NICE single technology appraisals completed during this period. We compared HTA results for matched condition-intervention pairs by G-BA and NICE, and explored other factors including therapeutic area, clinical effectiveness and cost-effectiveness.Results: NICE issued guidance for 88 technologies (125 subgroups) and recommended 67/88 technologies (99/125 subgroups). G-BA completed 105 appraisals (226 subgroups) and determined additional benefit for 64/105 appraisals (90/226 subgroups). We identified 37 matched pairs; for 24/37 drugs, evaluations diverged. NICE recommended 78% (29/37) of technologies appraised, whereas G-BA confirmed additional benefit for 57% (21/37) only (p < 0.05).Conclusions: NICE evaluates new drugs more favorably than G-BA. However, our analysis suggests differences by therapeutic area. Results indicate that different methods are associated with systematic differences in HTA outcomes. | ||
| 650 | 4 | |a Condition-intervention pair | |
| 650 | 4 | |a early benefit assessment | |
| 650 | 4 | |a evaluation | |
| 650 | 4 | |a health technology assessment | |
| 650 | 4 | |a single technology appraisal | |
| 700 | 1 | |a Schlander, Michael |d 1959- |e VerfasserIn |0 (DE-588)1036904652 |0 (DE-627)751411957 |0 (DE-576)389587710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of pharmacoeconomics and outcomes research |d Abingdon : Taylor & Francis Group, 2001 |g 19(2019), 4, Seite 453-462 |h Online-Ressource |w (DE-627)35569042X |w (DE-600)2090846-5 |w (DE-576)284039519 |x 1744-8379 |7 nnas |a Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany? |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:4 |g pages:453-462 |g extent:10 |a Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany? |
| 856 | 4 | 0 | |u https://doi.org/10.1080/14737167.2019.1559732 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/14737167.2019.1559732 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191126 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1036904652 |a Schlander, Michael |m 1036904652:Schlander, Michael |d 50000 |e 50000PS1036904652 |k 0/50000/ |p 2 |y j | ||
| 998 | |g 1200443306 |a Schäfer, Ramon |m 1200443306:Schäfer, Ramon |d 60000 |e 60000PS1200443306 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1683541901 |e 3550124651 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"title":[{"title_sort":"Expert review of pharmacoeconomics and outcomes research","title":"Expert review of pharmacoeconomics and outcomes research"}],"pubHistory":["1.2001 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 17.05.18"],"part":{"issue":"4","year":"2019","text":"19(2019), 4, Seite 453-462","extent":"10","volume":"19","pages":"453-462"},"id":{"zdb":["2090846-5"],"issn":["1744-8379"],"eki":["35569042X"]},"origin":[{"publisher":"Taylor & Francis Group ; Future Drugs ; Expert Reviews ; Informa UK","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisherPlace":"Abingdon ; London ; London ; London"}],"disp":"Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany?Expert review of pharmacoeconomics and outcomes research","recId":"35569042X"}],"note":["Gesehen am 26.11.2019"],"id":{"eki":["1683541901"],"doi":["10.1080/14737167.2019.1559732"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"30 Dec 2018"}],"name":{"displayForm":["Ramon Schaefer & Michael Schlander"]},"recId":"1683541901","person":[{"family":"Schäfer","role":"aut","given":"Ramon","display":"Schäfer, Ramon"},{"family":"Schlander","role":"aut","given":"Michael","display":"Schlander, Michael"}],"title":[{"title_sort":"Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany?","title":"Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany?"}],"physDesc":[{"extent":"10 S."}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a SCHAEFERRAISTHENATIO3020 | ||